查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1587591

到 2030 年基因型鉴定检测市场预测：按产品、技术、应用、最终用户和地区进行的全球分析

Genotyping Assay Market Forecasts to 2030 - Global Analysis By Product, Technology, Application, End User and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2024 年全球基因型鉴定检测市场规模将达到 200.9 亿美元，预计到 2030 年将达到 484.4 亿美元，预测期内复合年增长率为 15.8%。

基因型鉴定测定是一种分子生物学方法，用于检查个体和生物体基因序列的差异。识别特定的遗传标记，例如单核苷酸多态性 (SNP)、插入、缺失和拷贝数变异，以了解遗传性状、遗传倾向和疾病感受性。基因型鉴定测定广泛应用于遗传学、药物基因组学和个人化医疗等研究领域。

据世界卫生组织 (WHO) 称，特异性在控制遗传疾病方面越来越多地使用基因型鉴定检测，目前超过 70% 的全基因组关联研究 (GWAS) 都针对风险因素。 。

遗传性疾病增加

全球遗传疾病（包括癌症和遗传性疾病）的增加增加了对高效诊断工具的需求。透过使用基因型鉴定测定来识别导致这些疾病的基因突变，可以进行早期诊断和早期疗育。基因型鉴定对于发现可以指南治疗选择的肿瘤 DNA 突变至关重要，例如在肿瘤学中。此外，寻求疾病预防和管理策略的患者和医疗保健专业人员对基因检测的认识不断提高，也影响了这一趋势。

昂贵的试剂和设备

基因型鉴定技术，尤其是次世代定序(NGS) 和微阵列分析等先进技术，需要对专用设备和试剂进行大量投资。定序平台、微阵列扫描仪和其他必要基础设施的初始成本可能令人望而却步，特别是对于小型实验室和医疗设施而言。试剂和消耗品的持续支出也加剧了这种财务负担。此外，这种高成本结构限制了资源有限环境中的获取，从而阻碍了基因型鉴定技术在临床诊断和研究环境中的广泛应用。

扩大农业生物技术的应用

基因型鉴定测定在农业生物技术中的使用正在迅速扩大，提供了盈利的市场扩张机会。基因型鉴定在动物育种、作物改良以及抗病性和产量增加等理想性状的发现的应用正在扩大。到2050年，世界人口预计将接近100亿，迫切需要能够保障粮食安全的永续农业。此外，基因型鉴定分析可以支持显着提高农业復原力和生产力的作物（GMO）和标记辅助选择（MAS）方法的开发。

资料解释与管理的复杂性

基因型鉴定平台会产生大量复杂的遗传资料，包括结构变异、拷贝数变异和单核苷酸多态性 (SNP)。由于其复杂性，处理、评估和解释这些资料面临许多挑战。为了从基因组资料集集中获得重要的见解，研究人员通常需要先进的生物资讯工具和知识。由于缺乏标准化分析流程而导致结果不一致，可能会阻碍基因型鉴定测定在临床和研究环境中的有效使用。

COVID-19 的影响：

COVID-19 大流行为基因型鉴定检测市场带来了机会和挑战。最初，大流行透过扰乱供应链、减少工人运转率以及将资源转移到与大流行相关的紧急业务来扰乱基因型鉴定实验室的运作。然而，随着危机的进展，对基因分型服务的需求显着增加，特别是用于识别病毒基因突变的 COVID-19 基因分型试剂套件。由于越来越重视阐明基因突变和倾向，市场不断扩大，刺激了该领域的技术创新和研究。这次疫情也引起了人们对个人化医疗和快速诊断重要性的关注，进一步巩固了基因型鉴定分析在未来医疗保健规划中的使用。

预计药物基因体学领域在预测期内将是最大的领域。

由于对定製药物治疗的需求不断增加以及对个人化医疗的重视，药物基因体学领域在基因型鉴定检测市场中占有最大份额。随着医疗保健专业人员寻求根据患者的基因图谱确定最佳治疗策略，遗传性和危及生命的疾病数量的增加正在推动对药物基因体学测试的需求。此外，监管机构越来越多地鼓励将药物基因组学纳入药物开发程序，也推动了该市场的成长。

诊断实验室产业预计在预测期内复合年增长率最高。

在基因型鉴定检测市场中，诊断实验室领域预计将以最高的复合年增长率成长。这种增长是由基因检测和诊断需求的不断增长所推动的，特别是随着医疗保健转向更个人化的治疗计划。为了做出及时、准确的诊断，诊断实验室对于进行基因型鉴定测定至关重要，这有助于发现与各种疾病相关的遗传变异。此外，技术发展和高通量基因分型技术的发展提高了实验室能力，从而增加了测试量并缩短了周转时间。

占比最大的地区：

由于先进的医疗系统、大量的研发支出以及 Thermo Fisher Scientific 和 Illumina 等行业巨头的存在，北美地区占据了基因型鉴定检测的最大市场占有率。北美在全球市场中占据很大份额，部分原因是遗传患者病率上升以及对个人化医疗的日益关注。该地区拥有充足的公共和私人资金用于基因组学研究，加速了尖端基因型鉴定技术的采用。

复合年增长率最高的地区：

基因型鉴定检测市场预计将以亚太地区最高的复合年增长率成长。推动这一增长的因素包括蓬勃发展的製药和生物製药行业、不断增加的研发支出以及需要尖端医疗保健解决方案的人口老化。由于卫生系统的发展和对基因检测益处的认识不断提高，中国和印度等国家正在引领这一扩张。此外，对生物技术和基因组学研究的大量投资正在加速基因型鉴定技术的传播，预计亚太地区将在未来几年成为全球基因型鉴定检测市场的主要参与者。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争标基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球基因型鉴定检测市场：依产品

  • 试剂和套件
  • 基因型鉴定服务
  • 装置
    • 音序器和放大器
    • 分析仪
  • 生物资讯学
    • 软体
    • 服务

第六章全球基因型鉴定检测市场：依技术分类

  • 聚合酵素链锁反应
    • 即时聚合酵素链锁反应
    • 数位聚合酵素链锁反应
  • 微阵列
  • 定序
    • 次世代定序
    • 焦磷酸测序
    • 桑格序列
  • 毛细管电泳
    • 扩增片段长度多态性
    • 限制性内切酶片段长度多态性
    • 单链证实的多态性
  • 基质辅助雷射解吸/电离飞行时间法
  • 其他技术

第七章全球基因型鉴定检测市场：依应用分类

  • 药物基因组学
  • 诊断与个人化医疗
  • 动物遗传学
  • 农业生物技术
  • 其他用途

第八章全球基因型鉴定检测市场：依最终用户分类

  • 製药和生物製药公司
  • 诊断实验室
  • 学术研究所
  • 其他最终用户

第九章全球基因型鉴定检测市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十一章 公司概况

  • F. Hoffmann-La Roche Ltd.
  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific, Inc
  • Danaher Corporation
  • Genewiz, Inc
  • Eurofins Scientific SE
  • Agilent Technologies, Inc
  • Roche Diagnostics Limited
  • Illumina, Inc
  • GE HealthCare
  • Promega Corporation
  • Merck KGAA
  • Integrated DNA Technologies, Inc.
  • Qiagen NV
  • Perkinelmer, Inc
Product Code: SMRC27661

According to Stratistics MRC, the Global Genotyping Assay Market is accounted for $20.09 billion in 2024 and is expected to reach $48.44 billion by 2030 growing at a CAGR of 15.8% during the forecast period. A genotyping assay is a molecular biology method that examines differences in an individual's or organisms genetic sequence. In order to comprehend inherited traits, genetic predispositions, and disease susceptibility, it identifies particular genetic markers, such as single nucleotide polymorphisms (SNPs), insertions, deletions, or copy number variations. In research domains such as genetics, pharmacogenomics, and personalized medicine, genotyping assays are extensively employed.

According to the World Health Organization (WHO), genotyping assays are increasingly being used in the global effort to control hereditary diseases, with over 70% of current genome-wide association studies (GWAS) utilizing these assays to identify risk factors and develop population-specific health strategies.

Market Dynamics:

Driver:

Growing incidence of genetic conditions

The need for efficient diagnostic tools has increased due to the rise in genetic disorders worldwide, including cancer and hereditary diseases. Early diagnosis and intervention are made possible by the identification of genetic mutations that contribute to these conditions through the use of genotyping assays. Genotyping, for instance, is essential in oncology to find tumor DNA mutations that can guide treatment choices. Additionally, this trend is also being influenced by patients' and healthcare professionals' increasing awareness of genetic testing as they look for preventative and management strategies for illnesses.

Restraint:

Expensive reagents and equipment

Investing heavily in specialized equipment and reagents is necessary for genotyping technologies, especially sophisticated techniques like next-generation sequencing (NGS) and microarray analysis. Particularly for smaller research labs and medical facilities, the upfront expenses for sequencing platforms, microarray scanners, and other required infrastructure can be unaffordable. This financial burden is also made worse by the continuous expenses of reagents and consumables. Additionally, this high cost structure prevents genotyping technologies from being widely used in clinical diagnostics and research settings due to limited access in resource-constrained settings.

Opportunity:

Expanding uses of agricultural biotechnology

Genotyping assay use in agricultural biotechnology is growing quickly, offering a profitable market expansion opportunity. The use of genotyping in animal breeding, crop improvement, and the discovery of desirable traits like disease resistance and yield enhancement is growing. Sustainable agricultural practices that can guarantee food security are desperately needed, as the world's population is expected to approach 10 billion people by 2050. Furthermore, the development of genetically modified organisms (GMOs) and marker-assisted selection (MAS) methods, which can greatly increase agricultural resilience and productivity, can be aided by genotyping assays.

Threat:

Complexity of interpreting and managing data

Large volumes of intricate genetic data, such as structural variants, copy number variations, and single nucleotide polymorphisms (SNPs), are produced by genotyping platforms. There are many difficulties in handling, evaluating, and interpreting this data because of its complexity. In order to derive significant insights from genomic datasets, researchers frequently need sophisticated bioinformatics tools and knowledge. The efficient use of genotyping assays in clinical and research contexts can be hampered by inconsistent results caused by the absence of standardized analysis pipelines.

Covid-19 Impact:

There were both opportunities and challenges for the genotyping assay market as a result of the COVID-19 pandemic. At first, the pandemic hindered genotyping lab operations by upsetting supply chains, reducing the availability of workers, and redirecting resources to urgent pandemic-related tasks. However, the demand for genotyping services increased significantly as the crisis progressed, especially for COVID-19 genotyping kits, which are used to identify the virus's genetic variations. The market grew as a result of the increased emphasis on comprehending genetic variations and predispositions, which spurred innovation and research in the area. The pandemic also brought attention to the significance of personalized medicine and quick diagnostics, which further cemented the use of genotyping assays in future medical plans.

The Pharmacogenomics segment is expected to be the largest during the forecast period

Due to the growing demand for customized drug therapies and the emphasis on personalized medicine, the pharmacogenomics segment commands the largest share of the genotyping assay market. Healthcare professionals are looking to determine the best course of treatment for patients based on their genetic profiles, which has increased demand for pharmacogenomic testing due to the rise in hereditary and life-threatening disorders. Moreover, growth in this market is also being driven by regulatory agencies' growing recommendations for the incorporation of pharmacogenomics into drug development procedures.

The Diagnostic Laboratories segment is expected to have the highest CAGR during the forecast period

In the market for genotyping assays, the diagnostic laboratories segment is anticipated to grow at the highest CAGR. The rising need for genetic testing and diagnostics, especially as healthcare shifts to more individualized treatment plans, is what is driving this growth. In order to make timely and precise diagnoses, diagnostic labs are essential for performing genotyping assays, which help find genetic variations linked to a variety of diseases. Additionally, technological developments and the creation of high-throughput genotyping techniques are improving laboratory capabilities, enabling greater testing volumes and quicker turnaround times.

Region with largest share:

Due to its sophisticated healthcare system, substantial R&D expenditures, and the presence of industry titans like Thermo Fisher Scientific and Illumina, the North American region commands the largest market share for genotyping assays. Due in large part to the rising incidence of genetic disorders and the growing focus on personalized medicine, North America held a significant share of the global market. The adoption of cutting-edge genotyping technologies has been accelerated in the region due to strong public and private funding for genomics research.

Region with highest CAGR:

The market for genotyping assays is anticipated to grow at the highest CAGR in the Asia-Pacific region. A thriving pharmaceutical and biopharmaceutical sector, rising R&D expenditures, and an aging population that requires cutting-edge healthcare solutions are some of the factors driving this growth. Due to their developing healthcare systems and rising awareness of the advantages of genetic testing, nations like China and India are leading the way in this expansion. Moreover, it is anticipated that the region's substantial investments in biotechnology and genomics research will accelerate the uptake of genotyping technologies, positioning Asia Pacific as a major player in the global genotyping assay market in the years to come.

Key players in the market

Some of the key players in Genotyping Assay market include F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc, Danaher Corporation, Genewiz, Inc, Eurofins Scientific SE, Agilent Technologies, Inc, Roche Diagnostics Limited, Illumina, Inc, GE HealthCare, Promega Corporation, Merck KGAA, Integrated DNA Technologies, Inc., Qiagen N.V. and Perkinelmer, Inc.

Key Developments:

In April 2024, Bio-Rad Laboratories, Inc. a global leader in life science research and clinical diagnostics products, announced a collaboration agreement with Oncocyte Corporation, a precision diagnostics company, to develop and commercialize transplant monitoring products using Bio-Rad's Droplet Digital(TM) PCR (ddPCR(TM)) instruments and reagents.

In December 2023, Roche announced the entry into a definitive agreement to acquire select parts of the LumiraDx group related to LumiraDx's innovative Point of Care technology. Following closing of the transaction, which is expected by mid-2024, the acquired entities will be fully integrated into Roche Diagnostics.

In October 2023, Thermo Fisher Scientific Inc. entered into a definitive agreement to acquire CorEvitas, a provider of regulatory-grade, real-world evidence for approved medical treatments and therapies, from Audax Private Equity, for $912.5 million in cash. CorEvitas will become part of Thermo Fisher's Laboratory Products and Biopharma Services segment.

Products Covered:

  • Reagents & Kits
  • Genotyping Services
  • Instruments
  • Bioinformatics

Technologies Covered:

  • Polymerase Chain Reaction
  • Microarrays
  • Sequencing
  • Capillary Electrophoresis
  • Matrix-assisted Laser Desorption/Ionization-time of Flight Mass Spectrometry
  • Other Technologies

Applications Covered:

  • Pharmacogenomics
  • Diagnostics and Personalized Medicine
  • Animal Genetics
  • Agricultural Biotechnology
  • Other Applications

End Users Covered:

  • Pharmaceutical & Biopharmaceutical Companies
  • Diagnostic Laboratories
  • Academic & Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Genotyping Assay Market, By Product

  • 5.1 Introduction
  • 5.2 Reagents & Kits
  • 5.3 Genotyping Services
  • 5.4 Instruments
    • 5.4.1 Sequencers and Amplifiers
    • 5.4.2 Analyzers
  • 5.5 Bioinformatics
    • 5.5.1 Software
    • 5.5.2 Services

6 Global Genotyping Assay Market, By Technology

  • 6.1 Introduction
  • 6.2 Polymerase Chain Reaction
    • 6.2.1 Real-Time Polymerase Chain Reaction
    • 6.2.2 Digital Polymerase Chain Reaction
  • 6.3 Microarrays
  • 6.4 Sequencing
    • 6.4.1 Next-Generation Sequencing
    • 6.4.2 Pyrosequencing
    • 6.4.3 Sanger Sequencing
  • 6.5 Capillary Electrophoresis
    • 6.5.1 Amplified Fragment Length Polymorphism
    • 6.5.2 Restriction Fragment Length Polymorphism
    • 6.5.3 Single-Strand Confirmation Polymorphism
  • 6.6 Matrix-assisted Laser Desorption/Ionization-time of Flight Mass Spectrometry
  • 6.7 Other Technologies

7 Global Genotyping Assay Market, By Application

  • 7.1 Introduction
  • 7.2 Pharmacogenomics
  • 7.3 Diagnostics and Personalized Medicine
  • 7.4 Animal Genetics
  • 7.5 Agricultural Biotechnology
  • 7.6 Other Applications

8 Global Genotyping Assay Market, By End User

  • 8.1 Introduction
  • 8.2 Pharmaceutical & Biopharmaceutical Companies
  • 8.3 Diagnostic Laboratories
  • 8.4 Academic & Research Institutes
  • 8.5 Other End Users

9 Global Genotyping Assay Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 F. Hoffmann-La Roche Ltd.
  • 11.2 Bio-Rad Laboratories, Inc.
  • 11.3 Thermo Fisher Scientific, Inc
  • 11.4 Danaher Corporation
  • 11.5 Genewiz, Inc
  • 11.6 Eurofins Scientific SE
  • 11.7 Agilent Technologies, Inc
  • 11.8 Roche Diagnostics Limited
  • 11.9 Illumina, Inc
  • 11.10 GE HealthCare
  • 11.11 Promega Corporation
  • 11.12 Merck KGAA
  • 11.13 Integrated DNA Technologies, Inc.
  • 11.14 Qiagen N.V.
  • 11.15 Perkinelmer, Inc

List of Tables

  • Table 1 Global Genotyping Assay Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Genotyping Assay Market Outlook, By Product (2022-2030) ($MN)
  • Table 3 Global Genotyping Assay Market Outlook, By Reagents & Kits (2022-2030) ($MN)
  • Table 4 Global Genotyping Assay Market Outlook, By Genotyping Services (2022-2030) ($MN)
  • Table 5 Global Genotyping Assay Market Outlook, By Instruments (2022-2030) ($MN)
  • Table 6 Global Genotyping Assay Market Outlook, By Sequencers and Amplifiers (2022-2030) ($MN)
  • Table 7 Global Genotyping Assay Market Outlook, By Analyzers (2022-2030) ($MN)
  • Table 8 Global Genotyping Assay Market Outlook, By Bioinformatics (2022-2030) ($MN)
  • Table 9 Global Genotyping Assay Market Outlook, By Software (2022-2030) ($MN)
  • Table 10 Global Genotyping Assay Market Outlook, By Services (2022-2030) ($MN)
  • Table 11 Global Genotyping Assay Market Outlook, By Technology (2022-2030) ($MN)
  • Table 12 Global Genotyping Assay Market Outlook, By Polymerase Chain Reaction (2022-2030) ($MN)
  • Table 13 Global Genotyping Assay Market Outlook, By Real-Time Polymerase Chain Reaction (2022-2030) ($MN)
  • Table 14 Global Genotyping Assay Market Outlook, By Digital Polymerase Chain Reaction (2022-2030) ($MN)
  • Table 15 Global Genotyping Assay Market Outlook, By Microarrays (2022-2030) ($MN)
  • Table 16 Global Genotyping Assay Market Outlook, By Sequencing (2022-2030) ($MN)
  • Table 17 Global Genotyping Assay Market Outlook, By Next-Generation Sequencing (2022-2030) ($MN)
  • Table 18 Global Genotyping Assay Market Outlook, By Pyrosequencing (2022-2030) ($MN)
  • Table 19 Global Genotyping Assay Market Outlook, By Sanger Sequencing (2022-2030) ($MN)
  • Table 20 Global Genotyping Assay Market Outlook, By Capillary Electrophoresis (2022-2030) ($MN)
  • Table 21 Global Genotyping Assay Market Outlook, By Amplified Fragment Length Polymorphism (2022-2030) ($MN)
  • Table 22 Global Genotyping Assay Market Outlook, By Restriction Fragment Length Polymorphism (2022-2030) ($MN)
  • Table 23 Global Genotyping Assay Market Outlook, By Single-Strand Confirmation Polymorphism (2022-2030) ($MN)
  • Table 24 Global Genotyping Assay Market Outlook, By Matrix-assisted Laser Desorption/Ionization-time of Flight Mass Spectrometry (2022-2030) ($MN)
  • Table 25 Global Genotyping Assay Market Outlook, By Other Technologies (2022-2030) ($MN)
  • Table 26 Global Genotyping Assay Market Outlook, By Application (2022-2030) ($MN)
  • Table 27 Global Genotyping Assay Market Outlook, By Pharmacogenomics (2022-2030) ($MN)
  • Table 28 Global Genotyping Assay Market Outlook, By Diagnostics and Personalized Medicine (2022-2030) ($MN)
  • Table 29 Global Genotyping Assay Market Outlook, By Animal Genetics (2022-2030) ($MN)
  • Table 30 Global Genotyping Assay Market Outlook, By Agricultural Biotechnology (2022-2030) ($MN)
  • Table 31 Global Genotyping Assay Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 32 Global Genotyping Assay Market Outlook, By End User (2022-2030) ($MN)
  • Table 33 Global Genotyping Assay Market Outlook, By Pharmaceutical & Biopharmaceutical Companies (2022-2030) ($MN)
  • Table 34 Global Genotyping Assay Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 35 Global Genotyping Assay Market Outlook, By Academic & Research Institutes (2022-2030) ($MN)
  • Table 36 Global Genotyping Assay Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.